Aberrant crypt foci: Are they intermediate endpoints of colon carcinogenesis in humans?

Current Opinion in Gastroenterology

Volumn 25, Issue 1, 2009, Pages 59-65

  Gupta, Akshay K ^a   Schoerr, Robert E ^b,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c PUH   (United States)

Author keywords

Aberrant crypt foci; Biomarker; Colorectal cancer; High magnification colonoscopy

Indexed keywords

BIOLOGICAL MARKER;

CHROMOENDOSCOPY; COLON CARCINOGENESIS; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; ENDOSCOPY; GENE MUTATION; HISTOLOGY; HUMAN; MISMATCH REPAIR; NONHUMAN; PREVALENCE; RECTUM ADENOMA; REVIEW;

ADENOMA; COLON; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; HUMANS; INTESTINAL MUCOSA; PRECANCEROUS CONDITIONS; PREVALENCE; RECTUM; RISK FACTORS; WORLD HEALTH;

EID: 58349100295     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32831db286     Document Type: Review

References (53)

1. Gupta AK, Pretlow TP, Schoen RE Aberrant crypt foci: what we know and what we need to know. Clin Gastroenterol Hepatol 2007; 5:526-533,
2. Bird RP. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 1987; 37:147-151.
3. Fenoglio-Preiser CM, Noffsinger A. Aberrant crypt foci: a review. Toxicol Pathol 1999;27:632-642.
4. Corpet DE, Tache S. Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer 2002; 43:1-21.
5. Pretlow TP, Barrow BJ, Ashton WS, et al. Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res 1991; 51:1564-1567.
6. Yokota T, Sugano K, Hondo H, et al. Detection of aberrant crypt foci by magnifying colonoscopy. Gastrointest Endosc 1997; 46:61-65.
7. Seike K, Koda K, Oda K, et al. Assessment of rectal aberrant crypt foci by standard chromoscopy and its predictive value for colonic advanced neoplasms. Am J Gastroenterol 2006; 101:1362-1369.
8. Cho NL, Redston M, Zauber AG, et al. Aberrant Crypt Foci in the Adenoma •• Prevention with Celecoxib Trial. Cancer Prev Res 2008; 1:OF1-OF11. This is a human study that employs ACF as an intermediate endpoint, nested within an adenoma prevention trial that uses celecoxib.
9. Lance P, Hamilton SR. Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention. Cancer Prev Res 2008; 1:OF2 - OF5.
10. Mutch M, Schoen RE, Fleshman JW, et al. Prevalence and Risk Factors for Aberrant Crypt Foci: an ancillary study to the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Gastroenterology 2008; 132:20.
11. Schoen RE, Mutch M, Rall C, et al. The natural history of aberrant crypt foci. •• Gastrointest Endosc 2008; 67:1097-1102. The first study on the natural history of ACF, showing that only 43% of ACF can be reidentified 1 year later.
12. Gupta AK, Pinsky P, Rall C, et al. Performance of high magnification colonoscopy (HMC) in detecting aberrant crypt foci (ACF). Gastroenterology 2008; 134:A445-A446.
13. Takayama T, Katsuki S, Takahashi Y, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998; 339:1277-1284.
14. Rudolph RE, Dominttz JA, Lampe JW, et al. Risk factors for colorectal cancer in relation to number and size of aberrant crypt foci in humans. Cancer Epidemiol Biomarkers Prev 2005; 14:605-608.
15. Hurlstone DP, Karajeh M, Sanders DS, et al. Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: biomarkers for flat and depressed neoplasia. Am J Gastroenterol 2005; 100:1283-1289.
16. Adler DG, Gostout CJ, Sorbi D, et al. Endoscopic identification and quantification of aberrant crypt foci in the human colon. Gastrointest Endosc 2002; 56:657-662.
17. Kim J, Ng J, Arozulllah A, et al. Aberrant crypt focus size predicts distal polyp • histopathology. Cancer Epidemiol Biomarkers Prev 2008; 17:1155-1162. A large scale study on ACF prevalence, in which, for the first time, the entire left colon was examined for ACF in all study participants.
18. Roncucci L, Pedroni M, Fante R, et al. Cell kinetic evaluation of human colonic aberrant crypts. (Colorectal Cancer Study group of the University of Modena and the Healthcare District 16, Modena, Italy). Cancer Res 1993; 53:3726-3729.
19. Shpitz B, Bomstein Y, Mekori Y, et al. Aberrant crypt foci in human colons: distribution and histomorphologic characteristics. Hum Pathol 1998; 29:469-475.
20. Roncucci L, Stamp D, Medline A, et al. Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Hum Pathol 1991;22:287-294.
21. Roncucci L, Medline A, Bruce WR. Classification of aberrant crypt foci and microadenomas in human colon. Cancer Epidemiol Biomarkers Prev 1991; 1:57-60.
22. Siu IM, Pretlow TG, Amini SB, Pretlow TP. Identification of dysplasia in human colonic aberrant crypt foci. Am J Pathol 1997; 150:1805-1813.
23. Bouzourene H, Chaubert P, Seetentag W. et al. Aberrant crypt foci in patients with neoplastic and nonneoplastic colonic disease. Hum Pathol 1999; 30:66-71.
24. Pretlow TP, Brasitus TA, Fulton NC, et al. K-ras mutations in putative preneoplastic lesions in human colon. J Natl Cancer Inst 1993; 85:2004-2007.
25. Smith AJ, Stem HS, Penner M, et al. Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res 1994; 54:5527-5530.
26. Yamashita N, Minamoto T, Ochiai A, et al. Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. Gastroenterology 1995; 108:434-440.
27. Nucci MR, Robinson CR, Longo P, et al. Phenotypic and genotypic characteristics of aberrant crypt foci in human colorectal mucosa. Hum Pathol 1997; 28:1396-1407.
28. Otori K, Konishi M, Sugiyama K, et al. Infrequent somatic mutation of the adenomatous polyposis coli gene in aberrant crypt foci of human colon tissue. Cancer 1998; 83:896-900.
29. Takayama T, Ohi M, Hayashi T, et al. Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. Gastroenterology 2001; 121:599-611.
30. Jen J, Powell SM, Papadopoulos N, et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res 1994; 54:5523-5526.
31. Rosenberg DW, Yang S, Pleau DC, et al. Mutations in BRAF and KRAS differentially distinguish serrated versus nonserrated hyperplastic aberrant crypt foci in humans. Cancer Res 2007; 67:3551-3554.
32. Siu IM, Robinson DR, Schwartz S, et al. The identification of monoclonality in human aberrant crypt foci. Cancer Res 1999; 59:63-66.
33. Beach R, Chan AO, Wu TT, et al. BRAF mutations in aberrant crypt foci and hyperplastic polyposis. Am J Pathol 2005; 166:1069-1075.
34. Marra G, Bdand CR. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst 1995; 87:1114-1125.
35. Augenlicht LH, Richards C, Corner G, Pretlow TP. Evidence for genomic instability in human colonic aberrant crypt foci. Oncogene 1996; 12:1767-1772.
36. Heinen CD, Shivapurkar N, Tang Z, et al. Microsatellite instability in aberrant crypt foci from human colons. Cancer Res 1996; 56:5339-5341.
37. Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C. The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer 2003; 3:695-701.
38. Luo L, Li B, Pretlow TP. DNA alterations in human aberrant crypt foci and colon cancers by random primed polymerase chain reaction. Cancer Res 2003;63:6166-6169.
39. Hao XP, Pretlow TG, Rao JS, Pretlow TP. Beta-catenin expression is altered in human colonic aberrant crypt foci. Cancer Res 2001; 61:8085-8088.
40. Sena P, Saviano M, Monni S, et al. Subcellular localization of beta-catenin and APC proteins in colorectal preneoplastic and neoplastic lesions. Cancer Lett 2006;241:203-212.
41. Chan AO, Broaddus RR, Houlihan PS, et al. CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol 2002; 160:1823-1830.
42. Luo L, Chen WD, Pretlow TP. CpG island methylation in aberrant crypt foci and cancers from the same patients, Int J Cancer 2005; 115:747-751.
43. Li H, Myeroff L, Smiraglia D, et al. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci U S A 2003; 100:8412-8417.
44. Greenspan EJ, Jablonski MA, Rajan TV, et al. Epigenetic alterations in RASSF1A in human aberrant crypt foci. Carcinogenesis 2006; 27:1316-1322.
45. Toyota M, Ahuja N, One-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999; 96:8681-8686.
46. Moxon D, Raza M, Kenney R, et al. Relationship of aging and tobacco use with the development of aberrant crypt foci in a predominantly African-American population. Clin Gastroenterol Hepatol 2005; 3:271-278.
47. Kukitsu T, Takayama T, Miyanishi K, et al. Aberrant crypt foci as precursors of the dysplasia-carcinoma sequence in patients with ulcerative colitis. Clin Cancer Res 2008; 14:48-54.
48. Stevens RG, Swede H, Heinen CD, et al. Aberrant crypt foci in patients with a positive family history of sporadic colorectal cancer. Cancer Lett 2007; 248:262-268.
49. Shpitz B, Klein E, Buklan G, et al. Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer. Gut 2003; 52:1598-1601.
50. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50:113-130.
51. Stevens RG, Pretlow TP, Hurlstone DP, et al. Comment re: 'Sporadic Aberrant Crypt Foci Are Not a Surrogate Endpoint for Colorectal Adenoma Prevention' and 'Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial'. Cancer Prev Res 2008; 1:215-216.
52. Zauber AG, Bertagnolli MM. Comment re: 'Sporadic Aberrant Crypt Foci Are Not a Surrogate Endpoint for Colorectal Adenoma Prevention' and 'Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial'. Cancer Prev Res 2008; 1:216.
53. Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004; 36:417-422.